Schwarz J-M, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, Herraiz LA, Tai VW, Bergeron N, Bersot TP et al..  2015.  Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat.. J Clin Endocrinol Metab. 100(6):2434-42.
Ling H, Waterworth DM, Stirnadel HA, Pollin TI, Barter PJ, Y Kesaniemi A, Mahley RW, McPherson R, Waeber G, Bersot TP et al..  2009.  Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study.. Obesity (Silver Spring). 17(4):737-44.
Stirnadel H, Lin X, Ling H, Song K, Barter P, Y Kesaniemi A, Mahley RW, McPherson R, Waeber G, Bersot TP et al..  2008.  Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study.. Atherosclerosis. 197(2):868-76.
Barter P, Y McPherson R, Song K, Y Kesaniemi A, Mahley RW, Waeber G, Bersot TP, Mooser V, Waterworth D, Grundy SM.  2007.  Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia.. J Clin Endocrinol Metab. 92(6):2041-5.
Mahley RW, Bersot TP.  2006.  High density lipoprotein cholesterol in coronary artery patients: is it as low as expected? Anadolu Kardiyol Derg. 6(1):94-6;authorreply96.
Yu Y, Wyszynski DF, Waterworth DM, Wilton SD, Barter PJ, Y Kesaniemi A, Mahley RW, McPherson R, Waeber G, Bersot TP et al..  2005.  Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia.. J Lipid Res. 46(10):2202-13.
Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Y Kesaniemi A, Mahley RW, McPherson R, Waeber G, Bersot TP, Sharma SS et al..  2005.  Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).. Am J Cardiol. 95(2):194-8.
Mahley RW, Can S, Ozbayrakçi S, Bersot TP, Tanir S, K Palaoğlu E, Pépin GM.  2005.  Modulation of high-density lipoproteins in a population in istanbul, Turkey, with low levels of high-density lipoproteins.. Am J Cardiol. 96(4):547-55.
Shohet RV, Vega GL, Bersot TP, Mahley RW, Grundy SM, Guerra R, Cohen JC.  2002.  Sources of variability in genetic association studies: insights from the analysis of hepatic lipase (LIPC).. Hum Mutat. 19(5):536-42.
Mahley RW, Arslan P, Pekcan G, Pépin GM, Ağaçdiken A, Karaağoğlu N, Rakicioğlu N, Nursal B, Dayanikli P, Palaoğlu KE et al..  2001.  Plasma lipids in Turkish children: impact of puberty, socioeconomic status, and nutrition on plasma cholesterol and HDL.. J Lipid Res. 42(12):1996-2006.
Bersot TP, Vega GL, Grundy SM, Palaoğlu KE, Atagündüz P, Ozbayrakçi S, Gökdemir O, Mahley RW.  1999.  Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population.. J Lipid Res. 40(3):432-8.
Vega GL, Gao J, Bersot TP, Mahley RW, Verstraete R, Grundy SM, White A, Cohen JC.  1998.  The -514 polymorphism in the hepatic lipase gene (LIPC) does not influence androgen-mediated stimulation of hepatic lipase activity.. J Lipid Res. 39(7):1520-4.
Bersot TP, Russell SJ, Thatcher SR, Pomernacki NK, Mahley RW, Weisgraber KH, Innerarity TL, Fox CS.  1993.  A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during a study of the prevalence of this disorder.. J Lipid Res. 34(7):1149-54.
Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ.  1990.  Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.. J Lipid Res. 31(8):1337-49.
Rall SC, Newhouse YM, Clarke HR, Weisgraber KH, McCarthy BJ, Mahley RW, Bersot TP.  1989.  Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant.. J Clin Invest. 83(4):1095-101.
Bersot TP, Innerarity TL, Pitas RE, Rall SC, Weisgraber KH, Mahley RW.  1986.  Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages.. J Clin Invest. 77(2):622-30.
Innerarity TL, Hui DY, Bersot TP, Mahley RW.  1986.  Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions.. Adv Exp Med Biol. 201:273-88.
Innerarity TL, Bersot TP, Arnold KS, Weisgraber KH, Davis PA, Forte TM, Mahley RW.  1984.  Receptor binding activity of high-density lipoproteins containing apoprotein E from abetalipoproteinemic and normal neonate plasma.. Metabolism. 33(2):186-95.
Rall SC, Weisgraber KH, Innerarity TL, Bersot TP, Mahley RW, Blum CB.  1983.  Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.. J Clin Invest. 72(4):1288-97.
Weisgraber KH, Rall SC, Bersot TP, Mahley RW, Franceschini G, Sirtori CR.  1983.  Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I.. J Biol Chem. 258(4):2508-13.
Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR.  1980.  A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins.. J Clin Invest. 66(5):901-7.
Mahley RW, Innerarity TL, Bersot TP, Lipson A, Margolis S.  1978.  Alterations in human high-density lipoproteins, with or without increased plasma-cholesterol, induced by diets high in cholesterol.. Lancet. 2(8094):807-9.
Bersot TP, Mahley RW, Brown MS, Goldstein JL.  1976.  Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts.. J Biol Chem. 251(8):2395-8.
Mahley RW, Bersot TP, LeQuire VS, Levy RI, Windmueller HG, Brown WV.  1970.  Identity of very low density lipoprotein apoproteins of plasma and liver Golgi apparatus.. Science. 168(3929):380-2.